Score Overview
Explore the 2021 public Archive ranking →
Where Standard Biotools Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. LAB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 0.61 | — |
1 Year2025-10-23 | $ 1.38 | -56.12% |
5 Years2021-10-22 | $ 5.21 | -88.38% |
10 Years2016-10-21 | $ 5.03 | -87.96% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 |
|---|---|---|---|---|
| Price | $ 0.61 | $ 1.38 | $ 5.21 | $ 5.03 |
| Return | — | -56.12% | -88.38% | -87.96% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 84M | -$ 87M | $ 476M |
| 2025 | $ 85M | -$ 74M | $ 187M |
| 2024 | $ 174M | -$ 138M | $ 292M |
| 2023 | $ 106M | -$ 74M | $ 114M |
| 2022 | $ 97M | -$ 190M | $ 165M |
| 2021 | $ 130M | -$ 59M | $ 28M |
| 2020 | $ 138M | -$ 53M | $ 68M |
| 2019 | $ 117M | -$ 64M | $ 58M |
| 2018 | $ 112M | -$ 59M | $ 95M |
| 2017 | $ 101M | -$ 60M | $ 63M |
| 2016 | $ 104M | -$ 75M | $ 59M |
| 2015 | $ 114M | -$ 53M | $ 94M |
| 2014 | $ 116M | -$ 52M | $ 115M |
| 2013 | $ 71M | -$ 15M | $ 84M |
| 2012 | $ 52M | -$ 19M | $ 80M |
| 2011 | $ 42M | -$ 22M | $ 53M |
| 2010 | $ 33M | -$ 16M | $ 5M |
| 2009 | $ 25M | -$ 19M | $ 14M |
| 2008 | $ 15M | -$ 29M | $ 17M |
| 2007 | $ 7M | -$ 25M | $ 40M |
| 2006 | $ 6M | -$ 23M | $ 25M |
Standard Biotools Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 138M to $ 85M and net income went from -$ 53M to -$ 74M. Revenue increased in 2 of those 5 years; net income in 2.
Across Standard Biotools Inc's full reported history, from 2006 to 2025, revenue grew from $ 6M to $ 85M and net income went from -$ 23M to -$ 74M. Revenue increased in 65% of the years measured; net income in 45%.
Standard Biotools Inc currently holds a 20-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.
Membership
Explore LAB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
